Angiotensin-converting enzyme 2 (ACE2) is a novel component of the renin-angiotensin system that could counterbalance the growth-promoting function of angiotensin-converting enzyme (ACE). Our previous results have shown that ACE2 is lowly expressed in pancreas, and widely down-regulated in pancreatic cancer tissues and cells. In the present study, we investigated the effect of restoration of ACE2 expression on the growth of pancreatic cancer. We found that restoration of ACE2 protein suppressed cell proliferation, motility and increased the sensitivity to hypoxia induced injury in BxPC3 and SW1990 cell lines. Stably transfected cells overexpressing ACE2 exhibited decreased tumorigenicity and delayed tumor growth, both in vitro and in vivo. In addition, restoration of ACE2 expression mediated by adenovirus vector significantly inhibited the established tumor growth, strongly enhanced the anti-tumor activity of gemcitabine in a pancreatic cancer xenograft model in vivo, and significantly prolonged the survival time of animals bearing tumor xenografts. These results provide evidence that ACE2 plays a pivotal role in the development of pancreatic cancer, and suggest that ACE2 is a promising candidate for pancreatic cancer treatment.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.canlet.2011.03.011 | DOI Listing |
Clin Cancer Res
January 2025
Memorial Sloan Kettering Cancer Center, New York, NY, United States.
Purpose: Recent clinical advances with the approval of antibody-drug conjugates targeting Trop-2 such as sacituzumab-govitecan and datopotomab-deruxtecan have garnered tremendous interest for their therapeutic efficacy in numerous tumor types including breast and lung cancers. ImmunoPET can stratify tumor avidity, clarifying patient eligibility for ADC therapy as well as a diagnostic companion during therapy. Slow antibody circulation requires days to reach optimal imaging timepoints.
View Article and Find Full Text PDFBiomacromolecules
January 2025
Weldon School of Biomedical Engineering, Purdue University, West Lafayette, Indiana 47907, United States.
Pancreatic ductal adenocarcinoma (PDAC) is characterized by a dense extracellular matrix (ECM) exhibiting high stiffness and fast stress relaxation. In this work, gelatin-based viscoelastic hydrogels were developed to mimic the compositions, stiffness, and fast stress relaxation of PDAC tissues. The hydrogels were cross-linked by gelatin-norbornene-boronic acid (GelNB-BA), thiolated macromers, and a 1,2-diol-containing linear synthetic polymer PHD.
View Article and Find Full Text PDFArq Bras Cir Dig
January 2025
D'Or Institute for Research and Education, Digestive Surgery Residency Program - Rio de Janeiro (RJ), Brazil.
In patients with synchronic liver colorectal metastasis, resection of the primary tumor and liver metastases is the only potentially curative strategy. In such cases, there is no consensus on whether resection of the primary tumor and metastases should be performed simultaneously or whether a staged approach should be performed (resection of the primary tumor and after, hepatectomy, or hepatectomy first). Patients with no bowel occlusion and with extensive liver disease are advised neoadjuvant oncological therapy.
View Article and Find Full Text PDFArq Bras Cir Dig
January 2025
Universidade de São Paulo, Faculty of Medicine - São Paulo (SP), Brazil.
Background: Pancreatic neuroendocrine tumors (PNETs) are uncommon and heterogeneous neoplasms, often exhibiting indolent biological behavior. Their incidence is rising, largely due to the widespread use of high-resolution imaging techniques, particularly influencing the diagnosis of sporadic non-functioning tumors, which account for up to 80% of cases. While surgical resection remains the only curative option, the impact of factors such as tumor grade, size, and type on prognosis and recurrence is still unclear.
View Article and Find Full Text PDFArq Bras Cir Dig
January 2025
Instituto D'Or de Pesquisa e Ensino, Digestive Surgery Program - Rio de Janeiro (RJ), Brazil.
Complete removal of metastatic disease and maintenance of an adequate liver remnant remains the only treatment option with curative intent concerning colorectal liver metastases. Surgery impacts on the long-term prognosis and complications adversely affect oncological results. The actual morbidity involving this scenario is debatable and estimated to be ranging from 15% to 50%.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!